DBV DBV Technologies SA

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

Montrouge, France, March 3, 2021

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company has changed the date of its previously scheduled financial results conference call and live audio webcast. The Company will now report its full year 2020 financial results and provide a general corporate update on Thursday, March 11th at 5:00pm ET (11:00pm CET).

The conference call is accessible via the below teleconferencing numbers, followed by the reference ID: 50114481.

  • United States: (866) 866-1333                             
  • Canada: (866) 215-5508
  • United Kingdom: 0808 238 9578                       
  • France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Company’s website: . A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies 

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact

Anne Pollak

DBV Technologies



Media Contact

Angela Marcucci

DBV Technologies

+1 646-842-2393

Attachment



EN
03/03/2021

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

Information Regarding the Total Number of Voting Rights and Total Numb...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date Total number of sharesTotal number of voting rights03/31/2026 296,042,447  Total gross of voting rights: 296,042,447  Total net* of voting rights: 295,914,379  * Net total = total number of voting rights attached t...

April 2, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions c...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345  Date Nombre totald’actionscomposant le capital socialNombre totalde droits de vote31/03/2026  296.042.447  Total brut des droits de vote :296.042.447  Total net* des droits de vote :295.914.379  *Total net = nombre total de dro...

April 2, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K a...

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies publie son « Form 10-K » américain et son Document d’...

DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025 Châtillon, France, le 26 mars 2026 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique de stade avancé (la « Société »), a annoncé aujourd'hui, au titre de l’exercice 2025, que le « Form 10-K » a été déposé auprès de la Securities and Exchange Commission (« SEC ») aux Etats-Unis, ainsi que le document d’enregistrement universel (« DEU 2025 »)...

March 26, 2026 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Reports Full Year 2025 Financial Results and Business...

DBV Technologies Reports Full Year 2025 Financial Results and Business Update Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Bolstered executive leadership team in preparation for BLA submission and potential approvalReported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 202...

March 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch